Email ID
Password
Scrip   
Nycomed fights pantoprazole loss to post growth
16 November 2009
Christopher Spillane

Nycomed's third-quarter net turnover crept up by almost 1% to €820 million despite losing patent exclusivity for its biggest selling product, pantoprazole (Protonix). Gross profits were also up, rising by 1% to €597 million.

Revenues for the gastro-oesophageal reflux disease (GORD)...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36